Posttraumatic Stress Disorder
2
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
M&
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 programVVC-delivered Massed Imaginal ExposureN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Merck & Co.Adjunctive asenapine
Alliance PharmaceuticalsD-cycloserine
Johnson & JohnsonVVC-delivered Massed Imaginal Exposure
NeuroneticsTranscranial Magnetic Stimulation
Clinical Trials (4)
Total enrollment: 82 patients across 4 trials
An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder
Start: Jun 2012Est. completion: Jul 201618 patients
Phase 4Completed
D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents
Start: Jun 2010Est. completion: Jun 201224 patients
Phase 2Completed
Telehealth-Massed Imaginal Exposure for PTSD
Start: Jan 2023Est. completion: Jan 20240
N/AWithdrawn
rTMS for PTSD Comorbid With Major Depressive Disorder
Start: Oct 2014Est. completion: Apr 201640 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
5 companies competing in this space